Facebook tracking pixel
S10.AI
ICD-10-CM · H71.90GeneralSystemic

Cholesteatoma

Understanding Cholesteatoma (Keratinizing cyst, Epidermoid cyst of the ear): This comprehensive guide covers diagnosis, clinical documentation, and medical coding for Cholesteatoma. Learn about symptoms, treatment options, and ICD-10 codes related to this keratinizing cyst of the ear. Find information for healthcare professionals, including best practices for accurate clinical documentation and coding for Cholesteatoma.

Also known as
Keratinizing cystEpidermoid cyst of the ear
Definition

Abnormal skin growth in the middle ear, often behind the eardrum.

Clinical signs

Hearing loss, ear drainage, dizziness, ear fullness or pressure.

Common settings

ENT clinic, audiology clinic, otolaryngology department.

Related Codes

ICD-10 Code Families

Complete code families applicable to H71.90

H71.9
Cholesteatoma of ear, unspecified
H72
Perforation of tympanic membrane
H90.0-H90.8
Conductive and sensorineural hearing loss
H65.0-H65.9
Nonsuppurative otitis media
Code Comparison

When to use each related code

DescriptionWhen to use
Abnormal skin growth in the middle ear.Use for a cyst-like mass of keratinizing squamous epithelium in the middle ear. Consider acquired or congenital.
Middle ear infection with fluid buildup.Use for middle ear fluid without active infection signs. Often follows acute otitis media. Consider duration and hearing impact.
Middle ear inflammation, often with infection.Use for acute ear pain, redness, and possible discharge. May involve bacterial or viral infection. Consider severity and complications.
Documentation

Best-practice checklist

  • ✓Cholesteatoma ICD-10 H71.9, H72, document location, type
  • ✓Keratinizing cyst: Document size, growth rate, symptoms
  • ✓Epidermoid cyst of ear: Specify acquired/congenital
  • ✓Ear exam findings: Describe appearance, discharge
  • ✓Imaging results: Include CT/MRI findings if performed
Coding & Audit Risks

Common pitfalls to avoid

Laterality Coding

Missing or incorrect laterality (right, left, bilateral) for cholesteatoma can lead to claim denials and inaccurate data reporting.

Congenital vs Acquired

Distinguishing between congenital and acquired cholesteatoma is crucial for accurate coding and impacts treatment and prognosis documentation.

Specificity of Location

Coding should specify the precise location of the cholesteatoma within the ear (e.g., middle ear, external auditory canal) to ensure correct reimbursement.

Mitigation

Best-practice tips

  • 01Document cholesteatoma type, site, size for accurate ICD-10 coding (H71.9, H72).
  • 02Timely surgical intervention prevents complications, ensure clear op notes & coding.
  • 03Monitor hearing tests, imaging studies crucial for diagnosis, document changes.
  • 04Detailed history including ear discharge, hearing loss aids proper CDI, coding.
  • 05Regular follow-up crucial after treatment, document recurrence for compliance.
Clinical Decision Support

Step-by-step checklist

  1. 1

    Conductive hearing loss present?

  2. 2

    Chronic ear discharge or otorrhea?

  3. 3

    Retraction pocket or pearly white mass visible?

  4. 4

    History of recurrent ear infections?

  5. 5

    Imaging (CT or MRI) confirms cholesteatoma?

Documentation Template

Ready-to-paste narrative

Patient presents with complaints consistent with cholesteatoma.  Symptoms include hearing loss (conductive hearing loss, sensorineural hearing loss, or mixed hearing loss), ear discharge (otorrhea), often foul-smelling, ear fullness, and occasional otalgia.  Physical examination reveals a pearly white mass or debris within the external auditory canal, often behind an intact tympanic membrane.  In some cases, the tympanic membrane may be perforated.  Differential diagnosis includes chronic otitis media, external otitis, and other middle ear masses.  Based on clinical findings and otoscopic examination, a diagnosis of cholesteatoma (keratinizing cyst, epidermoid cyst of the ear) is made.  Treatment options including surgical removal (mastoidectomy, tympanoplasty) were discussed with the patient.  Risks and benefits of the procedure were explained, and informed consent was obtained.  Follow-up care, including audiologic evaluation and potential hearing rehabilitation, was scheduled.  ICD-10 code H71.9 (cholesteatoma, unspecified) is applicable.  The medical necessity for surgical intervention is documented due to the risk of complications such as hearing loss progression, ossicular erosion, facial nerve paralysis, and intracranial extension.
FAQs

Common questions and answers

What are the most effective differential diagnosis strategies for cholesteatoma versus keratoma, considering their overlapping clinical presentations?+

Differentiating cholesteatoma from keratoma can be challenging due to similar presentations like otorrhea and conductive hearing loss. Key distinctions lie in the location and nature of the lesion. Cholesteatoma, a keratinizing cyst, typically involves the middle ear and mastoid, often eroding bone. Keratoma, confined to the external auditory canal, doesn't exhibit bone erosion. Otoscopic examination reveals a pearly white mass for cholesteatoma, while keratoma appears as a desquamating keratin plug. High-resolution CT imaging is crucial for confirming the diagnosis and assessing the extent of bony destruction in suspected cholesteatoma. Explore how incorporating detailed imaging protocols can improve diagnostic accuracy in challenging cases. Consider implementing a standardized approach to otoscopic examination and image interpretation for better differentiation between these conditions.

How can I manage recurrent cholesteatoma after surgical resection, specifically addressing persistent or residual disease in the middle ear and mastoid?+

Recurrent cholesteatoma following surgical resection poses a significant clinical challenge. Contributing factors include incomplete excision of the original cholesteatoma, difficult-to-access anatomical locations (e.g., sinus tympani, facial recess), and squamous epithelium migration into the middle ear. Management strategies for recurrent cholesteatoma necessitate a meticulous approach, including second-look surgery, often performed 6-12 months post-initial surgery, for early detection of recurrence. Canal wall down mastoidectomy or canal wall up mastoidectomy with regular endoscopic follow-up are surgical options. Postoperative care plays a vital role, with regular cleaning and debridement of the cavity crucial for preventing further recurrence. Learn more about advanced surgical techniques for recurrent cholesteatoma management and the role of long-term follow-up strategies.

Beyond surgical intervention, what are the latest medical management strategies for cholesteatoma, including emerging therapies and the role of topical agents in controlling infection and inflammation?+

While surgery remains the primary treatment for cholesteatoma, medical management is essential for controlling infection and inflammation, particularly pre and postoperatively. Topical antibiotic eardrops, such as quinolones or aminoglycosides, can address bacterial superinfection. Anti-inflammatory agents, like corticosteroids, can help reduce inflammation and edema. Emerging therapies under investigation include topical application of chitosan or other biomaterials to inhibit keratinocyte proliferation and migration. However, these are not yet standard practice. Regular aural toilet and careful monitoring are crucial. Consider implementing a protocol for perioperative medical management of cholesteatoma to minimize complications and optimize surgical outcomes. Explore how emerging research on topical therapies may influence future management strategies for this condition.

Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.

Coding standard: ICD-10-CM, current FY guidelines.